AnovulationCOLANCT02309047
The Cycle Disturbances, OLigomenorrhea and Amenorrhea (COLA) Study & Biobank
An observational study of Anovulation, run by UMC Utrecht at 1 site in Netherlands.
Trial summary
Through the COLA Study and Biobank the investigators hope to enable further identification of phenotype, endocrine, ethnic, and metabolic characteristics associated with menstrual cycle disturbances; and: the identification of genetic or other etiologic factors associated with cycle disturbances. Read more about this study
- Who is it for?
- Ages 18 to 45 years, women only
- Conditions the study is for
- Anovulation
- How many people
- 5,000 participants
- Where
- 1 siteNetherlands
- Study dates
- Oct 2004to Aug 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- No healthy volunteers
- Adult
Study population: Women with cycle disturbances are referred to the outpatient clinic specialized in cycle disturbances by 1st or 2nd line care providers for further diagnostic procedures.
Who may be able to join
- WHO I Hypogonadotropic hypoestrogenic status (previously: "hypothalamic amenorrhea")
- Low to normal serum FSH concentrations
- Low serum estradiol concentrations
- WHO II
- Amenorrhea or oligomenorrhea (mean cycle >35 days during the last 6 months)
- Normal serum FSH concentrations (<12 IU/L)
Show all 18Show fewer
- Absence of other causes for the cycle disturbance, including: normal prolactin concentrations (<1.0 IU/L), normal TSH concentrations (0.2 - 4.2 milliunits/L), abnormalities on ultrasonography.
- Within women with WHO II status, PCOS is diagnosed when at least 2 of the following criteria are met:
- Oligo-/anovulation
- Clinical and/ or biochemical hyperandrogenism
- Polycystic ovaries on ultrasonography
- WHO III
- POI: defined as secondary amenorrhea before the age of 40 years and basal FSH > 40 IU/L.
- IOF: defined as normal ovulatory cycles with raised basal FSH > 12 IU/L before the age of 40 years.
- TOF: defined as irregular cycles with raised basal FSH > 12 IU/L before the age of 40 years.
- Poor ovarian response: defined as less than 4 oocytes retrieved or cancellation in case of absent follicle growth after ovarian hyperstimulation with 300 IU gonadotropins.
- Early menopause: menopause occurring between age 40 and 45 years.
- Hypergonadotropic primary amenorrhea: primary amenorrhea with raised basal FSH > 12 IU/L.
Who cannot join
- Age: younger than 18 yrs.
- Regularly cycling women, with the exception of women with elevated basal FSH concentrations (IOF cases).
Trial locations and contacts
1 site in 1 country.
Netherlands1 site, 1 recruiting
- Recruiting
University Medical Center Utrecht
Utrecht, 3508GA
Bart CJ Fauser, professor, +31887557524, b.c.fauser@umcutrecht.nl
Nadine MP Daan, MD, +31877551044, n.m.p.daan@umcutrecht.nl
About this study
Through the COLA Study and Biobank the investigators hope to enable further identification of phenotype, endocrine, ethnic, and metabolic characteristics associated with menstrual cycle disturbances; and: the identification of genetic or other etiologic factors associated with cycle disturbances.
Read the detailed description
Population Women with cycle disturbances are referred to the outpatient clinic specialized in cycle disturbances by 1st or 2nd line care providers for further diagnostic procedures.
Inclusion criteria WHO I Hypogonadotropic hypoestrogenic status (previously: "hypothalamic amenorrhea")
- Low to normal serum follicle-stimulating hormone (FSH) concentrations
- Low serum estradiol concentrations
WHO II
- Amenorrhea or oligomenorrhea (mean cycle >35 days during the last 6 months)
- Normal serum FSH concentrations (<12 IU/L)
- Absence of other causes for the cycle disturbance, including: normal prolactin concentrations (<1.0 IU/L), normal thyroid stimulating hormone (TSH) concentrations (0.2 - 4.2 milli-International unit /L), abnormalities on ultrasonography.
Within women with WHO II status, polycystic ovary syndrome (PCOS) is diagnosed when at least 2 of the following criteria are met:
- Oligo-/anovulation
- Clinical and/ or biochemical hyperandrogenism
- Polycystic ovaries on ultrasonography
WHO III
- primary ovarian insufficiency (POI): defined as secondary amenorrhea before the age of 40 years and basal FSH > 40 IU/L.
- incipient ovarian failure (IOF): defined as normal-ovulatory cycles with raised basal FSH > 12 IU/L before the age of 40 years.
- transient ovarian failure (TOF): defined as irregular cycles with raised basal FSH > 12 IU/L before the age of 40 years.
- Poor ovarian response: defined as less than 4 oocytes retrieved or cancellation in case of absent follicle growth after ovarian hyperstimulation with 300 IU gonadotropins.
- Early menopause: menopause occurring between age 40 and 45 years.
- Hypergonadotropic primary amenorrhea: primary amenorrhea with raised basal FSH > 12 IU/L. Controls For analyses in which comparison with female controls are needed, data will be collected from existing population based cohorts, such as the EPIC cohort (Julius Center), or selected women included in the preconceptional cohort (PC, derived from the Department of Reproductive Medicine and Gynaecology in the University Medical Center Utrecht (UMCU), separate protocol in preparation).
Exclusion criteria
- Age: younger than 18 yrs.
- Regularly cycling women, with the exception of women with elevated basal FSH concentrations (IOF cases).
Study parameters In order to determine the phenotype characteristics of women with cycle disturbances, and to allow for the identification of genetic factors associated with cycle disturbances, the following parameters will be obtained.
- Age
- Ethnicity
- Social economic status and education
- Intoxications: smoking habits (previous and current), use of alcohol or drugs
- Medication and medication history
- Mental health (depression, stress and anxiety)
- Cycle regularity: age at menarche, use of (oral/intrauterine) contraceptives, mean duration of cycle, variation in cycle duration.
- Reproductive \& obstetric history: parity, time to pregnancy and pregnancy outcome, subfertility (including treatments)
- Medical history (including previous gonadotoxic treatment)
- Family history of diabetes mellitus, early menopause, cycle irregularities, subfertility, cardiovascular disease, endocrinological disease, congenital disorders
- Basic physical examination: systolic and diastolic blood pressure, height, weight (BMI), waist circumference, hip circumference
- Assessment of hirsutism, acne, Tanner sexual development stages.
- Ovarian reserve parameters: antral follicle count, ovarian volume, anti-müllerian hormone (AMH)
- luteinizing hormone (LH), FSH, prolactin, TSH, estradiol concentrations
- Androgen levels
- Lipid spectrum, glucose, insulin, High sensitivity C-reactive protein
- In POI specifically: bone density as assessed by dual-energy X-ray absorptiometry (DEXA), karyotype, fragile X premutation screening, presence of autoantibodies (against thyroid, ovaries, parietal cells and adrenal gland).
Participation in the COLA Biobank will consist of the additional withdrawal of two blood vials (one for DNA and one for serum sampling) obtained during the routine diagnostic procedure.
Relatives of the index patient:
When a familial tendency of the WHO status is suspected on the basis of family history of 1st and 2nd degree relatives, these relatives will be invited for participation of the study.
- Conditions
- Anovulation
- Medical subject headings
- Anovulation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| WHO anovulation | WHO I, II. III anovulation. See inclusion criteria |
What is being measured
The primary outcome is the main question the study is designed to answer.
hormonal classification
FSH, LH, Estradiol, Progesterone,Testosterone, Androstenedione, Sex hormone binding globulin (SHBG), Cortisol, TSH
Measured: within 6 weeks
metabolic profile
total cholesterol, triglycerides, LDL cholesterol, HDL cholesterol, insulin, glucose
Measured: within 6 weeks
ovarian reserve
anti mullerian hormone, FSH and antral follicle count.
Measured: within 6 weeks
Secondary outcomes (3)
autoimmunity in WHO 3- POI patients
antithyroid peroxidase, antiadrenal, antiparietal and antiovarian antibodies
Measured: within 3 months
bone density in WHO 3- POI patients
a dual-energy x-ray absorptiometry (DEXA) scan
Measured: within 3 months
genotype in WHO 3 POI patients
karotype, fragile X mental retardation 1 gene premutation carriership
Measured: within 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Dec 2014 (estimated)
- Study startOct 2004
- Primary completionJun 2022 (estimated)
- Study completionAug 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for AnovulationStudies of the same condition, open and under way.
- More trials run by UMC UtrechtThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 5,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- UMC Utrecht
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Bart CJM Fauser, UMC Utrecht
- Investigators
- Bart CJ Fauser, professor, Principal investigator, UMC Utrecht
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02309047
- Sponsor's protocol ID
- 12-645
- Acronym
- COLA
- Status last verified
- Oct 2021
- First submitted
- 12 Nov 2014
- Last updated
- 20 Oct 2021
- Results posted
- No
- Data monitoring committee
- No
Publications
Christ JP, Gunning MN, Meun C, Eijkemans MJC, van Rijn BB, Bonsel GJ, Laven JSE, Fauser BCJM. Pre-Conception Characteristics Predict Obstetrical and Neonatal Outcomes in Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2019 Mar 1;104(3):809-818. doi: 10.1210/jc.2018-01787.
PubMed 30590587Christ JP, Gunning MN, Palla G, Eijkemans MJC, Lambalk CB, Laven JSE, Fauser BCJM. Estrogen deprivation and cardiovascular disease risk in primary ovarian insufficiency. Fertil Steril. 2018 Apr;109(4):594-600.e1. doi: 10.1016/j.fertnstert.2017.11.035. Epub 2018 Mar 28.
PubMed 29605405
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Cycle Disturbances, OLigomenorrhea and Amenorrhea (COLA) Study & Biobank
- ClinicalTrials.gov ID
- NCT02309047
- Acronym / sponsor ID
- COLA / 12-645
- Conditions
- Anovulation
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 5,000 participants (estimated)
- Lead sponsor
- UMC UtrechtUniversity, hospital or other
- Study start
- Oct 2004 (actual)
- Primary completion
- Jun 2022 (estimated)
- Study completion
- Aug 2023 (estimated)
- First posted
- 5 Dec 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Through the COLA Study and Biobank the investigators hope to enable further identification of phenotype, endocrine, ethnic, and metabolic characteristics associated with menstrual cycle disturbances; and: the identification of genetic or other etiologic factors associated with cycle disturbances.
Detailed description
Population Women with cycle disturbances are referred to the outpatient clinic specialized in cycle disturbances by 1st or 2nd line care providers for further diagnostic procedures.
Inclusion criteria WHO I Hypogonadotropic hypoestrogenic status (previously: "hypothalamic amenorrhea")
- Low to normal serum follicle-stimulating hormone (FSH) concentrations
- Low serum estradiol concentrations
WHO II
- Amenorrhea or oligomenorrhea (mean cycle >35 days during the last 6 months)
- Normal serum FSH concentrations (<12 IU/L)
- Absence of other causes for the cycle disturbance, including: normal prolactin concentrations (<1.0 IU/L), normal thyroid stimulating hormone (TSH) concentrations (0.2 - 4.2 milli-International unit /L), abnormalities on ultrasonography.
Within women with WHO II status, polycystic ovary syndrome (PCOS) is diagnosed when at least 2 of the following criteria are met:
- Oligo-/anovulation
- Clinical and/ or biochemical hyperandrogenism
- Polycystic ovaries on ultrasonography
WHO III
- primary ovarian insufficiency (POI): defined as secondary amenorrhea before the age of 40 years and basal FSH > 40 IU/L.
- incipient ovarian failure (IOF): defined as normal-ovulatory cycles with raised basal FSH > 12 IU/L before the age of 40 years.
- transient ovarian failure (TOF): defined as irregular cycles with raised basal FSH > 12 IU/L before the age of 40 years.
- Poor ovarian response: defined as less than 4 oocytes retrieved or cancellation in case of absent follicle growth after ovarian hyperstimulation with 300 IU gonadotropins.
- Early menopause: menopause occurring between age 40 and 45 years.
- Hypergonadotropic primary amenorrhea: primary amenorrhea with raised basal FSH > 12 IU/L. Controls For analyses in which comparison with female controls are needed, data will be collected from existing population based cohorts, such as the EPIC cohort (Julius Center), or selected women included in the preconceptional cohort (PC, derived from the Department of Reproductive Medicine and Gynaecology in the University Medical Center Utrecht (UMCU), separate protocol in preparation).
Exclusion criteria
- Age: younger than 18 yrs.
- Regularly cycling women, with the exception of women with elevated basal FSH concentrations (IOF cases).
Study parameters In order to determine the phenotype characteristics of women with cycle disturbances, and to allow for the identification of genetic factors associated with cycle disturbances, the following parameters will be obtained.
- Age
- Ethnicity
- Social economic status and education
- Intoxications: smoking habits (previous and current), use of alcohol or drugs
- Medication and medication history
- Mental health (depression, stress and anxiety)
- Cycle regularity: age at menarche, use of (oral/intrauterine) contraceptives, mean duration of cycle, variation in cycle duration.
- Reproductive \& obstetric history: parity, time to pregnancy and pregnancy outcome, subfertility (including treatments)
- Medical history (including previous gonadotoxic treatment)
- Family history of diabetes mellitus, early menopause, cycle irregularities, subfertility, cardiovascular disease, endocrinological disease, congenital disorders
- Basic physical examination: systolic and diastolic blood pressure, height, weight (BMI), waist circumference, hip circumference
- Assessment of hirsutism, acne, Tanner sexual development stages.
- Ovarian reserve parameters: antral follicle count, ovarian volume, anti-müllerian hormone (AMH)
- luteinizing hormone (LH), FSH, prolactin, TSH, estradiol concentrations
- Androgen levels
- Lipid spectrum, glucose, insulin, High sensitivity C-reactive protein
- In POI specifically: bone density as assessed by dual-energy X-ray absorptiometry (DEXA), karyotype, fragile X premutation screening, presence of autoantibodies (against thyroid, ovaries, parietal cells and adrenal gland).
Participation in the COLA Biobank will consist of the additional withdrawal of two blood vials (one for DNA and one for serum sampling) obtained during the routine diagnostic procedure.
Relatives of the index patient:
When a familial tendency of the WHO status is suspected on the basis of family history of 1st and 2nd degree relatives, these relatives will be invited for participation of the study.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| WHO anovulation | – | –WHO I, II. III anovulation. See inclusion criteria |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Women with cycle disturbances are referred to the outpatient clinic specialized in cycle disturbances by 1st or 2nd line care providers for further diagnostic procedures.
Key inclusion criteria (18 listed)
- WHO I Hypogonadotropic hypoestrogenic status (previously: "hypothalamic amenorrhea")
- Low to normal serum FSH concentrations
- Low serum estradiol concentrations
- WHO II
- Amenorrhea or oligomenorrhea (mean cycle >35 days during the last 6 months)
Key exclusion criteria (2 listed)
- Age: younger than 18 yrs.
- Regularly cycling women, with the exception of women with elevated basal FSH concentrations (IOF cases).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
hormonal classification
Time frame: within 6 weeks
FSH, LH, Estradiol, Progesterone,Testosterone, Androstenedione, Sex hormone binding globulin (SHBG), Cortisol, TSH
metabolic profile
Time frame: within 6 weeks
total cholesterol, triglycerides, LDL cholesterol, HDL cholesterol, insulin, glucose
ovarian reserve
Time frame: within 6 weeks
anti mullerian hormone, FSH and antral follicle count.
3 secondary outcomes
autoimmunity in WHO 3- POI patients
Time frame: within 3 months
bone density in WHO 3- POI patients
Time frame: within 3 months
genotype in WHO 3 POI patients
Time frame: within 3 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2021.
- Derived from this study: PubMed 30590587Christ JP, Gunning MN, Meun C, Eijkemans MJC, van Rijn BB, Bonsel GJ, Laven JSE, Fauser BCJM. Pre-Conception Characteristics Predict Obstetrical and Neonatal Outcomes in Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2019 Mar 1;104(3):809-818. doi: 10.1210/jc.2018-01787.
- Derived from this study: PubMed 29605405Christ JP, Gunning MN, Palla G, Eijkemans MJC, Lambalk CB, Laven JSE, Fauser BCJM. Estrogen deprivation and cardiovascular disease risk in primary ovarian insufficiency. Fertil Steril. 2018 Apr;109(4):594-600.e1. doi: 10.1016/j.fertnstert.2017.11.035. Epub 2018 Mar 28.
- study informationLink provided by the sponsor.
Related trials for Anovulation
RecruitingPhase 1
Efficacy of Injectable Vitamin D Supplementation in Females With Polycystic Ovary Syndrome
Anovulatory Infertility
RecruitingPhase 2
A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea
Functional Hypothalamic Amenorrhea, FHA
Not yet recruitingObservational study
Half-dose vs Conventional-dose Cetrorelix in ICSI Cycles
Infertility, Infertility, Female
Recruiting
Sperm Preparation Prior to Intrauterine Insemination Study
Infertility, Infertility Secondary
Not yet recruiting
Ovarian Stromal Stiffness and Ovarian Reserve Parameters Via Transvaginal Shear Wave Elastography
Ovarian Reserve Markers, Ovarian Function
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bart CJ Fauser, professor principal investigator
UMC Utrecht
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Anovulation, run by UMC Utrecht at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 18 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 20 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
hormonal classification (time frame: within 6 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02309047, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2021.